AN02 is a CTLA-4 degrader that demonstrates potent anti-cancer activity in ovarian cancer research. This compound inhibits cell proliferation, clonogenicity, migration, and invasion of ovarian cancer cells while upregulating the expression of antigen-presenting cells (APC). AN02 mediates CTLA-4 degradation through the SMAD4 pathway, significantly reducing tumor growth in small xenograft models and reversing the immune-suppressive tumor environment. Additionally, when used in combination with Ipilimumab, AN02 enhances therapeutic efficacy and inhibits epithelial-mesenchymal transition, making it a valuable tool for studying ovarian cancer.
AN02 is a CTLA-4 degrader that demonstrates potent anti-cancer activity in ovarian cancer research. This compound inhibits cell proliferation, clonogenicity, migration, and invasion of ovarian cancer cells while upregulating the expression of antigen-presenting cells (APC). AN02 mediates CTLA-4 degradation through the SMAD4 pathway, significantly reducing tumor growth in small xenograft models and reversing the immune-suppressive tumor environment. Additionally, when used in combination with Ipilimumab, AN02 enhances therapeutic efficacy and inhibits epithelial-mesenchymal transition, making it a valuable tool for studying ovarian cancer.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
